Cable Hill Partners LLC Sells 80 Shares of Becton, Dickinson and Company (NYSE:BDX)

Cable Hill Partners LLC decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 4.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,541 shares of the medical instruments supplier’s stock after selling 80 shares during the quarter. Cable Hill Partners LLC’s holdings in Becton, Dickinson and Company were worth $372,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Livelsberger Financial Advisory purchased a new position in Becton, Dickinson and Company during the third quarter worth about $26,000. Ashton Thomas Securities LLC bought a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $33,000. Tompkins Financial Corp boosted its stake in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 46 shares during the last quarter. Sound Income Strategies LLC grew its holdings in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares in the last quarter. Finally, Kennebec Savings Bank purchased a new stake in shares of Becton, Dickinson and Company during the third quarter valued at approximately $46,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX opened at $231.26 on Thursday. The firm has a 50-day moving average price of $236.66 and a 200-day moving average price of $235.13. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $249.89. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $66.84 billion, a price-to-earnings ratio of 38.93, a PEG ratio of 1.72 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. Becton, Dickinson and Company’s revenue was up 6.9% compared to the same quarter last year. During the same period in the previous year, the business earned $3.42 EPS. Equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be issued a dividend of $1.04 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date is Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a yield of 1.80%. Becton, Dickinson and Company’s dividend payout ratio is 63.97%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Evercore ISI boosted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Raymond James decreased their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their target price for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, Stifel Nicolaus lifted their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $283.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.